GSK plc (LON: GSK)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 62.09B |
| Revenue (ttm) | 30.74B |
| Net Income (ttm) | 4.48B |
| Shares Out | 4.08B |
| EPS (ttm) | 1.09 |
| PE Ratio | 13.99 |
| Forward PE | 9.31 |
| Dividend | 0.58 (3.81%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 288,885 |
| Open | 1,531.50 |
| Previous Close | 1,522.50 |
| Day's Range | n/a |
| 52-Week Range | 1,330.19 - 1,823.50 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2024 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial StatementsNews
Evaluating Merck & Co Against Peers In Pharmaceuticals Industry
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comp...
Is GSK a Top-Value Stock Right Now?
GSK, a multinational pharma company, scans as a bargain.
GSK CEO and Fleming Initiative Chair on Fighting Drug-Resistant 'Superbugs'
Emma Walmsley, CEO of GSK and Ara Darzi, Executive Director of the Fleming Initiative and Imperial College's Director of the Institute of Global Health Innovation, on their efforts to combat the rise ...
GSK moves to new HQ in return to central London
Around 3,000 of the drug giant’s staff will be based at The Earnshaw building on the corner of New Oxford Street.
GSK to deliver over 36M flu shots for fall immunization drive
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for th...
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
According to a small study by Weill Cornell Medicine and New York-Presbyterian investigators, vaccinating mothers using Pfizer Inc’s (NYSE: PFE) vaccine against respiratory syncytial virus (RSV) duri...
GSK downgraded to Neutral at UBS
GSK stock downgraded to Neutral by UBS due to uncertainty on Zantac resolution timing despite strong franchises and valuation.
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Labour Party member Keir Starmer is set to become the new prime minister of the United Kingdom with a win over the Rishi Sunak -led Conservative Party. The win marks an end to 14 years of Conservative...
Will GSK Stock Rebound To Its 2022 Highs Of $47?
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over th...
CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
GSk snaps six straight days of losses
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1245643393-5b713f2d94e345bb80d85dc04d05f355.jpg)
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
GSK has purchased the rights to potential COVID-19 and flu vaccines being developed in collaboration with German biotech CureVac.
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Wednesday, GSK plc (NYSE: GSK) and CureVac N.V. (NASDAQ: CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize inve...
GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech ...
CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines
U.K. pharmaceutical giant GSK said the deal gives it the rights to develop, manufacture and commercialize messenger RNA-based candidate vaccines for flu and COVID-19.
GSK to Buy CureVacs Covid-19, Flu Vaccine Rights for Up to $1.56 Billion
CureVac to cut 30% of workforce as GSK buys rights to make flu, covid shots
GSK, CureVac Expand Licensing Agreement
Under a new licensing deal with CureVac, GSK will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19.
GSK signs €1.4bn mRNA vaccine deal with troubled biotech CureVac
New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to a...
GSK buys full rights to make COVID, influenza vaccines from CureVac
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euro...
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge
A Delaware judge rebuffed a request by GSK and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward.